Frontlight ResearchEarly access
CompletedNo phase
Role of 18F-FDG PET/CT in the Evaluation of Cavernous Sinus Syndrome: a Pilot Study
Key facts
- Who runs it
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Where
- India1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 54 people enrolled
- Started
- 1 Jul 2022
- Ended
- 30 Jun 2024
- Type of study
- Observational
- Treatments tested
- FDG radiotracer
- Record updated
- 6 December 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (6)Hide the full registry criteria
Who can take part
- Patients with age greater than or equal to 18 years,
- with newly diagnosed CSS,
- lesion seen on MRI in the CS, and
- willing to give written informed consent
Who cannot take part
- Patients already being treated (including steroids)
- Pregnant and lactating patients
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Cavernous sinus syndrome (CSS) can be caused by a wide range of inflammatory, malignant, benign, vascular and miscellaneous disorders. Even after modern advances, reaching the final etiological diagnosis remains a challenge in CSS. This study is planned to determine the role and incremental value of 18F-FDG PET/CT in characterising different cavernous sinus pathologies based on their metabolic activity and detecting extracranial involvement.
The group in the trial
- Treatment naive patients presenting with Cavernous Sinus Syndrome with cavernous sinus lesion on MRI
Treatment: FDG radiotracer
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 6 December 2024